RARE Daily

NeuroSense Joins EverythingALS Open Innovation Consortium

August 2, 2022

NeuroSense Therapeutics is joining the EverythingALS Open Innovation Forum, which consists of patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like amyotrophic lateral sclerosis.

EverythingALS was founded in 2020 with the mission of bringing technological innovations and data science to support efforts—from care to cure—for people with ALS. The non-profit conducts technology-based research to help track progression of ALS to be utilized for clinical endpoints. All of the organization’s data and insights from research are made available as open science for researchers, pharmaceutical companies, and other potential partners to collaborate.

In addition to providing financial support for ongoing research projects, NeuroSense’s strategic collaboration with EverythingALS will provide insight into patients’ needs and allow the company to better serve the ALS community.

Amyotrophic lateral sclerosis (ALS) affects as many as 30,000 people in the United States, with 5,000 new cases diagnosed each year. ALS is a difficult disease to diagnose as there is not one test or procedure to ultimately establish the diagnosis of the disease and it can take 12-18 months to diagnose by method of elimination. There is also no known cure for ALS and many clinical trials to find treatments are currently in motion.

NeuroSense is currently enrolling patients in PARADIGM, a phase 2b double blind, placebo controlled, multicenter clinical trial to evaluate its lead drug candidate for ALS, PrimeC, in Israel and expects to begin patient enrollment in the United States and European Union this quarter. Top-line results are expected in the second quarter of 2023.

PrimeC was tested in a phase 2a clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and demonstrated statistically significant changes in ALS-related biological markers.

In addition to providing financial support for ongoing research projects, NeuroSense’s strategic collaboration with EverythingALS will provide insight into patients’ needs and allow the company to better serve the ALS community.

“EverythingALS and NeuroSense are taking similar actions in the fight against neurological diseases, including conducting extensive biomarker research,” said Indu Navar, founder of the Peter Cohen Foundation, functioning as EverythingALS.  “NeuroSense’s innovative therapeutic approach tackles this complex disease from multiple angles. Collaboration is key to making giant strides toward the digital biomarkers to be used in clinical trials of ALS, and to ultimately work toward the discovery of a potential cure.”

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube